An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback